	US 12,257,298 B2
	Coronavirus vaccine
Che Ma, New Taipei (TW); Chi-Huey Wong, Taipei (TW); and Han-Yi Huang, Taoyuan (TW)
Assigned to ACADEMIA SINICA, Taipei (TW)
Appl. No. 18/005,573
Filed by ACADEMIA SINICA, Taipei (TW)
PCT Filed Apr. 12, 2022, PCT No. PCT/US2022/071682 § 371(c)(1), (2) Date Jan. 13, 2023, PCT Pub. No. WO2022/221837, PCT Pub. Date Oct. 20, 2022.
Claims priority of provisional application 63/190,199, filed on May 18, 2021.
Claims priority of provisional application 63/173,752, filed on Apr. 12, 2021.
Prior Publication US 2024/0016917 A1, Jan. 18, 2024
Int. Cl. A61K 39/215 (2006.01); A61P 31/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 31/04 (2018.01); A61K 2039/55505 (2013.01); A61K 2039/575 (2013.01)]

19 Claims

1. An immunogen, comprising a glycoengineered coronavirus spike protein comprising a plurality of truncated N-glycans, and one or more unmodified O-glycans, wherein the glycoengineered coronavirus spike protein consists of the amino acid sequence of SEQ ID NO: 2.